X-101360624-T-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 1P and 5B. PP2BP4BS2
The NM_000061.3(BTK):āc.720A>Cā(p.Glu240Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000562 in 1,210,003 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 16 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Genomes: š 0.000054 ( 0 hom., 0 hem., cov: 22)
Exomes š: 0.000056 ( 0 hom. 16 hem. )
Consequence
BTK
NM_000061.3 missense
NM_000061.3 missense
Scores
6
11
Clinical Significance
Conservation
PhyloP100: 1.38
Genes affected
BTK (HGNC:1133): (Bruton tyrosine kinase) The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), BTK. . Gene score misZ: 4.0394 (greater than the threshold 3.09). The gene has 90 curated pathogenic missense variants (we use a threshold of 10). The gene has 26 curated benign missense variants. GenCC has associacion of the gene with short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia, Bruton-type agammaglobulinemia, isolated growth hormone deficiency type III.
BP4
Computational evidence support a benign effect (MetaRNN=0.2804863).
BS2
High Hemizygotes in GnomAdExome4 at 16 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BTK | NM_000061.3 | c.720A>C | p.Glu240Asp | missense_variant | 8/19 | ENST00000308731.8 | NP_000052.1 | |
BTK | NM_001287344.2 | c.822A>C | p.Glu274Asp | missense_variant | 8/19 | NP_001274273.1 | ||
BTK | NM_001287345.2 | c.720A>C | p.Glu240Asp | missense_variant | 9/17 | NP_001274274.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000537 AC: 6AN: 111778Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33944
GnomAD3 genomes
AF:
AC:
6
AN:
111778
Hom.:
Cov.:
22
AF XY:
AC XY:
0
AN XY:
33944
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000600 AC: 11AN: 183419Hom.: 0 AF XY: 0.0000295 AC XY: 2AN XY: 67869
GnomAD3 exomes
AF:
AC:
11
AN:
183419
Hom.:
AF XY:
AC XY:
2
AN XY:
67869
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000565 AC: 62AN: 1098225Hom.: 0 Cov.: 31 AF XY: 0.0000440 AC XY: 16AN XY: 363579
GnomAD4 exome
AF:
AC:
62
AN:
1098225
Hom.:
Cov.:
31
AF XY:
AC XY:
16
AN XY:
363579
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000537 AC: 6AN: 111778Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33944
GnomAD4 genome
AF:
AC:
6
AN:
111778
Hom.:
Cov.:
22
AF XY:
AC XY:
0
AN XY:
33944
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
2
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
9
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
BTK-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 12, 2022 | The BTK c.720A>C variant is predicted to result in the amino acid substitution p.Glu240Asp. This variant has been reported in an individual with X-linked agammaglobulinemia, however there was no conclusion regarding pathogenicity of this variant (Abbott et al. 2013. PubMed ID: 24001798). This variant is reported in 0.011% of alleles in individuals of African descent in gnomAD, including two hemizygous individuals (http://gnomad.broadinstitute.org/variant/X-100615612-T-G). While this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
X-linked agammaglobulinemia with growth hormone deficiency Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 18, 2023 | This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 240 of the BTK protein (p.Glu240Asp). This variant is present in population databases (rs141590686, gnomAD 0.009%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with BTK-related conditions. ClinVar contains an entry for this variant (Variation ID: 461818). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on BTK protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
X-linked agammaglobulinemia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 26, 2020 | Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as 3B-VUS. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0109 - This gene is known to be associated with X-linked recessive disease. (N) 0200 - Variant is predicted to result in a missense amino acid change from a glutamic acid to an aspartic acid (exon 8). (N) 0253 - Variant is hemizygous. (N) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (10 heterozygotes, 0 homozygotes, 2 hemizygotes). (P) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (N) 0603 - Missense variant in a region that is highly intolerant to missense variation (high constraint region) (SH3 domain; PMID: 24001798, NCBI, Decipher, PDB). (P) 0705 - No comparable variants have previous evidence for pathogenicity. (N) 0808 - Previous reports of pathogenicity are inconclusive. This variant has been previously reported as VUS (ClinVar). In addition, it has been reported in a patient with X-linked agammaglobulinemia, however, there was no conclusion regarding pathogenicity. (N) 0905 - No segregation evidence has been identified for this variant. (N) 1007 - No published functional evidence has been identified for this variant. (N) 1208 - Inheritance information for this variant is not currently available. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.;.;D
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T;T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;.;.;M
PrimateAI
Uncertain
T
PROVEAN
Benign
.;N;.;D
REVEL
Benign
Sift
Uncertain
.;D;.;D
Sift4G
Benign
T;T;T;T
Polyphen
0.056, 0.0010
.;B;.;B
Vest4
MutPred
Gain of ubiquitination at K237 (P = 0.0609);Gain of ubiquitination at K237 (P = 0.0609);.;Gain of ubiquitination at K237 (P = 0.0609);
MVP
MPC
1.2
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at